Abcellera Biologics Inc (ABCL)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 12-2024 | 12-2023 | 12-2022 | 12-2021 | 12-2020 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -162,857 | -146,398 | 158,519 | 153,464 | 118,918 |
| Depreciation Amortization | 96,998 | 30,894 | 33,102 | 17,250 | 5,271 |
| Income taxes - deferred | N/A | N/A | N/A | -2,018 | 2,098 |
| Accounts receivable | N/A | 9,273 | 129,171 | 59,864 | -203,020 |
| Accounts payable and accrued liabilities | 10,635 | -15,104 | -2,094 | -3,237 | 6,601 |
| Other Working Capital | -25,843 | 13,225 | 29,825 | 41,672 | -116,701 |
| Other Operating Activity | -27,489 | 64,233 | -71,163 | -22,411 | 209,523 |
| Operating Cash Flow | $-108,556 | $-43,877 | $277,360 | $244,584 | $22,690 |
| Cash Flows From Investing Activities | |||||
| Change In Deposits | 172,796 | -110,573 | -253,351 | -247,102 | N/A |
| PPE Investments | -78,396 | -76,947 | -70,660 | -58,452 | -9,673 |
| Net Acquisitions | N/A | N/A | N/A | -11,457 | -87,643 |
| Purchase Of Investment | -8,699 | -58,339 | -43,048 | -47,857 | -17,464 |
| Purchase Sale Intangibles | N/A | -560 | -2,000 | 0 | -5,000 |
| Other Investing Activity | 35,708 | 24,751 | 14,434 | 32,621 | -5,000 |
| Investing Cash Flow | $121,409 | $-221,108 | $-352,625 | $-332,247 | $-119,780 |
| Cash Flows From Financing Activities | |||||
| Change In Short Term Borrowing | N/A | N/A | N/A | N/A | 89,990 |
| Debt Issued | 13,498 | 11,590 | 2,755 | 5,487 | 16,490 |
| Debt Repayment | N/A | N/A | N/A | N/A | -19,942 |
| Common Stock Issued | N/A | N/A | N/A | N/A | 522,840 |
| Other Financing Activity | -729 | -1,234 | -4,383 | -9,373 | 74,275 |
| Financing Cash Flow | $12,769 | $10,356 | $-1,628 | $-3,886 | $683,653 |
| Exchange Rate Effect | -2,617 | 589 | -9,599 | -1,425 | N/A |
| Beginning Cash Position | 160,610 | 414,650 | 501,142 | 594,116 | 7,553 |
| End Cash Position | 183,615 | 160,610 | 414,650 | 501,142 | 594,116 |
| Net Cash Flow | $23,005 | $-254,040 | $-86,492 | $-92,974 | $586,563 |
| Free Cash Flow | |||||
| Operating Cash Flow | -108,556 | -43,877 | 277,360 | 244,584 | 22,690 |
| Capital Expenditure | -78,396 | -76,947 | -70,660 | -58,452 | -9,673 |
| Free Cash Flow | -186,952 | -120,824 | 206,700 | 186,132 | 13,017 |